Core Viewpoint - 康宁杰瑞制药-B announced a share buyback on December 1, 2023, spending HKD 2.457 million to repurchase 236,000 shares at a price range of HKD 10.25 to HKD 10.48 per share [1] Summary by Category - **Company Actions** - 康宁杰瑞制药-B executed a buyback of 236,000 shares at a total cost of HKD 2.457 million [1] - The repurchase price per share ranged from HKD 10.25 to HKD 10.48 [1]

Core Viewpoint - Corning Incorporated announced a share buyback plan, intending to repurchase 236,000 shares at a cost of HKD 2.457 million on December 1, 2025 [1] Group 1 - The company plans to spend HKD 2.457 million for the buyback [1] - A total of 236,000 shares will be repurchased as part of this initiative [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年12月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

Group 1 - Corning Incorporated announced the issuance of 146,000 shares due to the exercise of options on November 27, 2025 [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced the issuance of 146,000 shares due to the exercise of options on November 27, 2025 [1] Summary by Category - **Company Announcement** - Corning Jereh Pharmaceutical-B will issue 146,000 shares as a result of option exercise [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康寧傑瑞生物製藥 呈交日期： 2025年11月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09966 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | | ...

Core Viewpoint - 康宁杰瑞制药-B (09966) announced a share buyback program, indicating confidence in its business outlook and intrinsic value, with a maximum repurchase amount of 30 million HKD [1] Group 1: Share Buyback Announcement - The board of 康宁杰瑞制药 decided on November 7 to repurchase ordinary shares from the open market, with a maximum amount of 30 million HKD [1] - The board believes that the current trading price does not accurately reflect the company's intrinsic value [1] - This buyback is expected to benefit the company and create value for its shareholders [1] Group 2: Previous Buyback Program - In October, 康宁杰瑞制药 announced a plan to repurchase up to 20 million HKD worth of shares [1]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) announced a share buyback plan, indicating confidence in its business outlook and intrinsic value, which has positively impacted its stock price [1] Group 1: Stock Performance - The stock price of Corning Jereh Pharmaceutical-B rose over 7% in the afternoon trading session, with a current increase of 5.06%, reaching HKD 10.18 [1] - The trading volume amounted to HKD 18.5499 million [1] Group 2: Share Buyback Announcement - The board of directors resolved on November 7 to repurchase ordinary shares from the open market, with a maximum buyback amount of HKD 30 million [1] - The board believes that the current trading price does not accurately reflect the company's intrinsic value [1] - This buyback is expected to benefit the company and create value for its shareholders [1] - In October, the company had already announced a plan to repurchase up to HKD 20 million in shares [1]

Core Viewpoint - The article discusses recent developments in the pharmaceutical industry, particularly focusing on new drug applications and innovations in cancer treatment, highlighting the competitive landscape and market potential for various companies involved in drug development [5][12][20]. Group 1: New Drug Applications - From May 24 to May 30, the National Medical Products Administration received applications for 9 new chemical drugs and biological products from 6 listed companies [5]. - Companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and Kangfang Biotech each submitted 2 clinical applications, while others like Canaan and Bai Jie Shen Zhou submitted 1 application each [6]. Group 2: Key Innovations in Cancer Treatment - Kangning Jereh's KN035, a subcutaneous PD-L1 inhibitor, has been submitted for clinical trials, potentially becoming the first of its kind globally. It targets multiple indications, with 3 applications already submitted and 7 ongoing clinical studies [12][13]. - KN035 offers advantages over traditional intravenous methods, including better patient compliance and reduced costs, which could enhance its market share [13]. - The competitive landscape includes existing PD-L1 inhibitors like Merck's Atezolizumab and AstraZeneca's Durvalumab, with KN035 targeting different cancer types [14]. Group 3: Dual Antibody Developments - Kangfang Biotech's AK104, a PD-1/CTLA-4 dual-specific antibody, has received approval for clinical trials, with 13 indications currently in phase II trials [17]. - The dual antibody approach is gaining traction due to the limitations of existing PD-1/L1 therapies, which have low efficacy rates in solid tumors [18]. - The market for dual antibodies is expected to grow significantly, with 217 candidates in various clinical stages globally [19]. Group 4: COVID-19 Vaccine Developments - CanSino's inhaled COVID-19 vaccine is in phase II trials and is applying for emergency use, which could enhance public acceptance due to its non-invasive administration method [20][21]. - Sinovac has expanded the emergency use of its vaccine to children aged 3 and above, with positive safety and efficacy results from clinical trials [24][25].

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 17, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks [1]. Group 1: Buyback Details - China Feihe (06186) repurchased 10.81 million shares for a total of 47.19 million yuan, representing 1.532% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 41.62 million yuan, accounting for 1.083% of its total share capital [2]. - Sinopec Limited (00386) repurchased 3.79 million shares for 16.73 million yuan, which is 0.120% of its total share capital [2]. Group 2: Other Notable Buybacks - Lianlian Digital (02598) repurchased 1.71 million shares for 13.67 million yuan, representing 2.608% of its total share capital [2]. - Linklogis Technology (09959) repurchased 2.65 million shares for 7.40 million yuan, accounting for 4.885% of its total share capital [2]. - Jitu Express (01519) repurchased 640,000 shares for 6.25 million yuan, which is 0.041% of its total share capital [2]. Group 3: Additional Companies - Mengniu Dairy (02319) repurchased 200,000 shares for 2.98 million yuan, representing 0.660% of its total share capital [2]. - Kangning Jereh Pharmaceutical (09966) repurchased 350,000 shares for 3.42 million yuan, accounting for 0.211% of its total share capital [3]. - Huajian Medical (01931) repurchased 593,000 shares for 3.64 million yuan, which is 0.660% of its total share capital [3].